"mutations in the KEAP1/NFE2L2 pathway occur in approximately 7% of lung adenocarcinomas with activating EGFR mutations at diagnosis. Patients with KEAP1/NFE2L2/CUL3 mutations display relative intrinsic resistance to EGFR TKIs with reduced time to treatment failure."xsd:string